Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.२१%
१,०९१.५१
-२.३०
-०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९१.५१——
SIXC
Communications
SIXC
Communications
SIXC
+०.२२%
६१०.११
+१.३४
+०.२२%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.३४%
१,२३७.९८
-१६.८३
-१.३४%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९३%
१,७४४.७१
-१६.४०
-०.९३%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४४.७१——
SIXM
Financials
SIXM
Financials
SIXM
-०.३७%
६४०.१८
-२.४०
-०.३७%
—६४२.५८६४४.८७६४८.४८६४०.१८——
SIXR
Staples
SIXR
Staples
SIXR
-०.१८%
८४९.५८
-१.५५
-०.१८%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२३%
२१७.४८
-०.५०
-०.२३%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.५२%
३,२६०.६९
+४८.८६
+१.५२%
—३,२११.८३३,२२७.२१३,२६८.३८३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६९%
९४२.४५
-६.५३
-०.६९%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.५२%
१,४६६.८०
-७.७२
-०.५२%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६६.८०——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२२%
२,३९७.५०
+५.३८
+०.२२%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
ATAI:NASDAQ
AtaiBeckley Inc
US$ ४.१४
-०.६०%
(-०.०२५) 1D
US$ ४.११
-०.५८% (-०.०२४)
After hours
Closed: मे १, १६:००:०४ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Open
US$ ४.१५
High
US$ ४.२०
Low
US$ ४.०८
Mkt. cap
१.५२ अरब
Avg. vol.
६५.७६ लाख
Volume
२३.५६ लाख
52-wk high
US$ ६.७२
52-wk low
US$ १.२९
EPS
-US$ २.९१
Beta
१.५७
Shares outstanding
३६.६९ करोड
No. of employees
९९
News stories
From sources across the web
Profile
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees९९
Founded२०१८
Headquarters-
Sector-
Websiteataibeckley.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
१५.५५ लाख
७.१९ लाख
७.४९ लाख
१०.६६ लाख
Cost of goods sold
१.०८ करोड
१.०५ करोड
१.४७ करोड
१.०९ करोड
Cost of revenue
१.०८ करोड
१.०५ करोड
१.४७ करोड
१.०९ करोड
Research and development expenses
-
५.८२ लाख
-
४०.०४ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
९९.८७ लाख
१.४९ करोड
१.४५ करोड
२.४४ करोड
Operating expense
९९.८७ लाख
१.५५ करोड
१.४५ करोड
२.८४ करोड
Total operating expenses
२.०८ करोड
२.६० करोड
२.९२ करोड
३.९३ करोड
Operating income
-१.९३ करोड
-२.५३ करोड
-२.८४ करोड
-३.८२ करोड
Other non operating income
-१.३० करोड
-६३.२९ लाख
-५.१२ करोड
१.४० करोड
EBT including unusual items
-२.६३ करोड
-२.७७ करोड
-६.१० करोड
-५४.४८ करोड
EBT excluding unusual items
-३.२५ करोड
-३.०२ करोड
-७.९२ करोड
-२.३७ करोड
Income tax expense
१.२८ लाख
६५.०० हजार
१.०२ लाख
३.०० हजार
Effective tax rate
-०.४९%
-०.२३%
-०.१७%
-
Other operating expenses
-
-
-
-
Net income
-२.६४ करोड
-२.७७ करोड
-६.११ करोड
-५४.४८ करोड
Net profit margin
-१,६९९.७४%
-३,८५६.६१%
-८,१५४.०७%
-५१,१०८.१६%
Earnings per share
-०.१५
-०.१४
-०.२८
-१.७३
Interest and investment income
१.८६ लाख
२.४८ लाख
५.०४ लाख
५.४२ लाख
Interest expense
-९.०० लाख
-२.६४ लाख
-
-
Net interest expenses
-७.१४ लाख
-१६.०० हजार
५.०४ लाख
५.४२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.९१ करोड
-२.५० करोड
-२.८२ करोड
-३.७९ करोड
Gain or loss from assets sale
-
-
-
६.९२ लाख
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer